A detailed history of Keybank National Association transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Keybank National Association holds 1,649 shares of KRYS stock, worth $262,669. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,649
Previous 1,972 16.38%
Holding current value
$262,669
Previous $362,000 17.4%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$174.7 - $213.66 $56,428 - $69,012
-323 Reduced 16.38%
1,649 $299,000
Q2 2024

Jul 31, 2024

SELL
$153.12 - $183.64 $66,300 - $79,516
-433 Reduced 18.0%
1,972 $362,000
Q1 2024

May 14, 2024

SELL
$108.01 - $179.35 $15,013 - $24,929
-139 Reduced 5.46%
2,405 $427,000
Q4 2023

Feb 13, 2024

BUY
$96.0 - $128.29 $244,224 - $326,369
2,544 New
2,544 $315,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.09B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Keybank National Association Portfolio

Follow Keybank National Association and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Keybank National Association, based on Form 13F filings with the SEC.

News

Stay updated on Keybank National Association with notifications on news.